Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C

Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00298714

Enrollment

Registered

2006-03-03

Start date

2003-03-31

Completion date

2006-01-31

Last updated

2007-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C, Liver Fibrosis

Keywords

Hepatitis C, Chronic

Brief summary

There is evidence on the beneficial effects of the administration of angiotensin II type 1 (AT1) receptors antagonists on liver fibrosis in hepatic stellate cells, experimental models of liver fibrosis in rodents and limited information in chronic hepatitis C with mild fibrosis. The purpose of this study is to investigate the effect of long-term administration of oral Losartan, an AT1 receptor antagonist, on liver fibrogenesis in patients with chronic hepatitis C and fibrosis F2-F3 (METAVIR score).

Interventions

DRUGLosartan

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

35 Years to 65 Years

Healthy volunteers

Inclusion criteria

* age between 35 and 65 years * chronic hepatitis C with intermediate fibrosis (F2-F3 in Metavir score). * non-responder or contraindication to antiviral therapy.

Exclusion criteria

* any other cause of liver disease * HIV positive * alcohol consumption * arterial hypertension * creatinine \> 1.5mg/dL * treatment with AT1 receptor antagonists or angiotensin converting enzyme inhibitors in the past 12 months. * antiviral therapy in the past 12 months * contraindications to oral losartan

Design outcomes

Primary

Measure	Time frame
Assessment of liver fibrogenesis by changes in gene expression of key mediators of liver fibrosis.	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026